SCHEMBL5008441

SCHEMBL5008441

Cc1ccc(F)cc1-n1nc(-c2ccccc2)cc1Nc1ccccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
RAB9A P51151 1/20 0.47
GFER P55789 1/20 0.46
TAS2R14 Q9NYV8 1/20 0.45
GRM5 P41594 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 2/20 0.44
MAPK1 P28482 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ADORA1 P30542 4/20 0.43
KDM4E B2RXH2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TP53 P04637 1/20 0.43
FABP4 P15090 1/20 0.43
KCNJ6 P48051 1/20 0.42
KCNJ5 P48544 1/20 0.42
KCNJ3 P48549 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008323 0.90 ADORA1 (0.54) MAPTRAB9AGFERGRM5ADORA1
SCHEMBL5010620 0.89 MAPT (0.51) MAPTRAB9AGFERTAS2R14GRM5
SCHEMBL5011993 0.88 ADORA1 (0.52) MAPTGFERMEN1LMNAGAA
SCHEMBL5008839 0.88 ADORA1 (0.47) MAPTRAB9AGRM5MEN1LMNA
SCHEMBL3974462 0.86 DHODH (0.48) MAPTRAB9AGRM5MEN1LMNA
SCHEMBL5008385 0.86 DHODH (0.46) MAPTADORA1
SCHEMBL27637093 0.85 MAPT (0.43) MAPTRAB9AGFERGRM5MEN1
SCHEMBL5008768 0.84 MAPK14 (0.53) MAPTGFERTAS2R14
SCHEMBL5007784 0.84 ADORA1 (0.51) MAPTGRM5ADORA1
SCHEMBL5008601 0.84 ADORA1 (0.47) MAPTGFERTAS2R14MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 MAPT 2420/4885RAB9A 3006/4885GFER 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.